Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation
Study sponsor: ImmunityBio, Inc. · IBRX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2030-12-31Estimated
Enrollment · participants70Estimated
Source updated2026-06-04Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.